Annual sales of Nubeqa could be as high as € 3 billion a year.
Orion partner Bayer has raised its assessment of the sales potential of the Nubeqa prostate cancer drug.
Bayer’s new estimate puts Nubeqa’s annual worldwide sales at its best in excess of € 3 billion. In the past, Bayer has estimated that Nubeqa’s annual global sales could exceed EUR 1 billion at best.
Nubeqa, or darolutamide, jointly developed by Orion and Bayer, has been approved in the EU as a new treatment for non-metastatic, hormone-resistant prostate cancer.
Bayerilla is the commercial rights to darolutamide worldwide and Orion is entitled to receive an annual staggered royalty from the worldwide sales of darolutamide.
The annual royalty level is approximately 20 percent, including product sales to Bayer. In the initial phase, the annual level of royalties will be slightly lower, and as sales increase, the annual level of royalties will increase. Orion is responsible for manufacturing the product for the global market and promotes sales in Europe together with Bayer.
In addition to the royalties, Orion is entitled to receive progressively increasing one-time milestone payments from Bayer, which may total EUR 280 million, depending on the future development of Nubeqa’s sales.
#Medicines #Orions #Bayers #anticancer #drug #times #sales #potential
